TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...

Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...

Studied over 36 weeks, in doses from 1.25 mg to 20 mg, patients taking amycretin experienced only "mild to moderate" gastrointestinal side effects, says Novo, and in exchange enjoyed a 9.7% average ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...

Average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19 in mid-2024 -- the lowest average recorded in a ...

The latter has made little difference: the popularity of Ozempic and other GLP-1 receptor agonists like Wegovy ... driven therapeutic which is safe, cheap and, crucially, side-effect free.

Designed to transform the treatment landscape for diabetes, metabolic syndrome and weight loss, Laxxon's breakthrough oral GLP-1 agonist, LXM.2, offers a once-daily robust alternative to ...

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have shown cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM). Given the risk factor overlap between neurovascular and ...

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the ...